Literature DB >> 16474399

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.

Ryan M Teague1, Blythe D Sather, Jilian A Sacks, Maria Z Huang, Michelle L Dossett, Junko Morimoto, Xiaoxio Tan, Susan E Sutton, Michael P Cooke, Claes Ohlén, Philip D Greenberg.   

Abstract

CD8+ T cells can mediate eradication of established tumors, and strategies to amplify tumor-reactive T-cell numbers by immunization or ex vivo expansion followed by adoptive transfer are currently being explored in individuals with cancer. Generating effective CD8+ T cell-mediated responses to tumors is often impeded by T-cell tolerance to relevant tumor antigens, as most of these antigens are also expressed in normal tissues. We examined whether such tolerant T cells could be rescued and functionally restored for use in therapy of established tumors. We used a transgenic T-cell receptor (TCR) mouse model in which peripheral CD8+ T cells specific for a candidate tumor antigen also expressed in liver are tolerant, failing to proliferate or secrete interleukin (IL)-2 in response to antigen. Molecular and cellular analysis showed that these tolerant T cells expressed the IL-15 receptor alpha chain, and could be induced to proliferate in vitro in response to exogenous IL-15. Such proliferation abrogated tolerance and the rescued cells became effective in treating leukemia. Therefore, high-affinity CD8+ T cells are not necessarily deleted by encounter with self-antigen in the periphery, and can potentially be rescued and expanded for use in tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474399     DOI: 10.1038/nm1359

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  95 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.

Authors:  Vinay V Vyas; Dominic Esposito; Terry L Sumpter; Trevor L Broadt; James Hartley; George C Knapp; Wei Cheng; Man-Shiow Jiang; John M Roach; Xiaoyi Yang; Steven L Giardina; George Mitra; Jason L Yovandich; Stephen P Creekmore; Thomas A Waldmann; Jianwei Zhu
Journal:  Biotechnol Prog       Date:  2011-12-09

Review 3.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 4.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

5.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 6.  Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

Review 9.  Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.

Authors:  Malcolm K Brenner; Fatma V Okur
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

10.  Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.

Authors:  Cary Hsu; John D Abad; Richard A Morgan
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.